Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Scientific Officer | February 17, 2023 | February 21, 2023 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | Director | May 28, 2020 | June 01, 2020 |
| TCR2 THERAPEUTICS INC.TCRR · Entity 94327 | Director | December 10, 2020 | December 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date February 17, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,000 |
Reported balance
After 2023-02-17 transaction · row 1
1 source rowRow 1 · 2023-02-17 · Grant · Acquired 38,500 · Balance 76,000 F1: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.34 · Expires 2033-02-16 | Direct | 77,000 |
Reported balance
After 2023-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-17 · Grant · Acquired 77,000 · Balance 77,000 F3: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 341,434 |
Reported balance
Holding disclosure · report date 2023-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 341,434 F2: Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2: Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Harpoon Therapeutics, Inc.
Report date May 28, 2020 · Filed June 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.59 · Expires 2030-05-27 | Direct | 10,167 |
Reported balance
After 2020-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-28 · Grant · Acquired 10,167 · Balance 10,167 F1: The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.59 · Expires 2030-05-27 | Direct | 2,584 |
Reported balance
After 2020-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-28 · Grant · Acquired 2,584 · Balance 2,584 F2: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date.
F2: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date.
TCR2 THERAPEUTICS INC.
Report date December 10, 2020 · Filed December 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.83 · Expires 2030-12-09 | Direct | 12,100 |
Reported balance
After 2020-12-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-10 · Grant · Acquired 12,100 · Balance 12,100 F2: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy APAK Solutions GmbH | 350,786 |
Reported balance
Holding disclosure · report date 2020-12-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 350,786 F1: The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F2: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 21, 2023 18:53 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0000899243-23-005731 · doc4.xml · derivative · entry 3 Baeuerle Patrick · CIK 0001362054 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2033-02-16 F3 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 18:53 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 38,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005731 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:48 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-22-006419 · doc4.xml · derivative · entry 3 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-10 F3 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:48 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006419 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · derivative · entry 4 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,114 Underlying: Common Stock · 11,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 11,000 | $28.45 | $312,950.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 11,000 | $4.30 | $47,300.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · derivative · entry 4 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,114 Underlying: Common Stock · 11,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 11,000 | $27.00 | $297,000.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. Read SEC document |
| August 10, 2021 Filed Aug 26, 2021 19:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 11,000 | $4.30 | $47,300.00 |
DisclosureSEC source: 0000899243-21-034306 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 17:37 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 286,665 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-21-001369 · doc4.xml · derivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,665 Underlying: Common Stock · 286,665 shares Expires 2031-01-06 F1 · derivative.exercise_date: The option represents a right to purchase a total of 286,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 06:16 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 12,100 | $0.00 Strike: $31.83 | $0.00 |
DisclosureSEC source: 0000899243-20-033475 · doc4.xml · derivative · entry 2 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,100 Underlying: Common Stock · 12,100 shares Expires 2030-12-09 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:38 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,584 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-20-033318 · doc4.xml · derivative · entry 2 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584 Underlying: Common Stock · 2,584 shares Expires 2030-05-27 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:38 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-20-033318 · doc4.xml · derivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2030-05-27 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 17:32 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,400 | $18.07 | $25,296.60 |
DisclosureSEC source: 0001209191-19-062169 · doc4.xml · nonDerivative · entry 3 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 262,136 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $17.57 to $18.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · ownership.nature: Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares. Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 17:32 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 10,417 | $16.90 | $176,061.88 |
DisclosureSEC source: 0001209191-19-062169 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 263,536 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $16.51 to $17.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · ownership.nature: Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares. Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 17:32 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 75,562 | $15.81 | $1,194,922.36 |
DisclosureSEC source: 0001209191-19-062169 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 273,953 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $15.51 to $16.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · ownership.nature: Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 17:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 84,907 | $15.44 | $1,310,964.08 |
DisclosureSEC source: 0000899243-19-030063 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By APAK Solutions GmbH Disclosed balance after: 350,786 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · price: $15.44 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $16.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 17:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 32,022 | $15.16 | $485,453.52 |
DisclosureSEC source: 0000899243-19-030063 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By APAK Solutions GmbH Disclosed balance after: 435,693 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: $15.16 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0001209191-19-034828 · doc4.xml · derivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2029-06-02 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:10 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 59,850 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001750019-19-000027 · wf-form4_155509981067242.xml · derivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,850 Underlying: Common Stock · 59,850 shares Expires 2029-04-10 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| February 07, 2019 Filed Mar 29, 2019 16:12 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,829 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021729 · doc4.xml · derivative · entry 1 Baeuerle Patrick · CIK 0001362054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 Underlying: Common Stock · 3,829 shares Expires 2029-02-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.